Previous Article | Next Article 
Infection and Immunity, February 1999, p. 700-707, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Characterization of Candidate Live Oral Salmonella
typhi Vaccine Strains Harboring Defined Mutations in
aroA, aroC, and htrA
David C.
Lowe,1,2
Tor C.
Savidge,3
Derek
Pickard,2
Lars
Eckmann,4
Martin F.
Kagnoff,4
Gordon
Dougan,5 and
Steven N.
Chatfield2,*
Department of Cellular Physiology, The
Babraham Institute, Babraham, Cambridge CB2
4AT,1
Vaccine Research Unit, Medeva
Group Research, Department of Biochemistry,2 and
Department of Biochemistry,5 Imperial
College of Science, Technology and Medicine, London SW7 2AY, and
Institute of Child Health, University of Birmingham,
Birmingham B16 8ET,3 United Kingdom, and
Laboratory of Mucosal Immunology, Department of Medicine,
University of California, San Diego, La Jolla,
California4
Received 18 June 1998/Returned for modification 23 September
1998/Accepted 24 November 1998
 |
ABSTRACT |
The properties of two candidate Salmonella typhi-based
live oral typhoid vaccine strains, BRD691 (S. typhi Ty2
harboring mutations in aroA and aroC) and
BRD1116 (S. typhi Ty2 harboring mutations in
aroA, aroC, and htrA), were
compared in a number of in vitro and in vivo assays. BRD1116 exhibited
an increased susceptibility to oxidative stress compared with
BRD691, but both strains were equally resistant to heat shock. Both
strains showed a similar ability to invade Caco-2 and HT-29
epithelial cells and U937 macrophage-like cells, but
BRD1116 was less efficient at surviving in epithelial cells than
BRD691. BRD1116 and BRD691 were equally susceptible to
intracellular killing within U937 cells. Similar findings were demonstrated in vivo, with BRD1116 being less able to survive and
translocate to secondary sites of infection when inoculated into the
lumen of human intestinal xenografts in SCID mice. However, translocation of BRD1116 to spleens and livers in SCID mice occurred as
efficiently as that of BRD691 when inoculated intraperitonally. The
ability of BRD1116 to increase the secretion of
interleukin-8 following infection of HT-29 epithelial cells was
comparable to that of BRD691. Therefore, loss of the HtrA protease in
S. typhi does not seem to alter its ability to invade
epithelial cells or macrophages or to induce proinflammatory cytokines
such as IL-8 but significantly reduces intracellular survival in human intestinal epithelial cells in vitro and in vivo.
 |
INTRODUCTION |
Salmonella strains
harboring genetically defined, attenuating mutations are attracting
interest for use as live, single-dose oral vaccines against typhoid and
as delivery vehicles for heterologous antigens (4-6, 12-16,
32-35). Following oral ingestion, Salmonella bacteria
invade the gut wall (8, 20), promoting neutrophil infiltration of the mucosa (21, 25) and subsequent
macrophage recruitment. The ability of Salmonella to invade
the epithelium (24) and to survive in macrophages
(1) is essential for virulence and may represent a major
factor in determining host restriction. Macrophages are believed to
play a role in immunity to Salmonella, but they may also
facilitate the dissemination of viable bacteria to deeper tissues, such
as the liver and spleen (3). Salmonella can also
induce apoptosis in macrophages, a factor which may further contribute
to virulence (7, 27).
Mutations in a number of different Salmonella genes have
been evaluated for the ability to attenuate virulence, including phoP and phoQ, which encode a two-component
regulator (13), and crp and cya, which
encode the cAMP receptor system (33). Salmonella strains harboring mutations in aro
genes, whose products are enzymes involved in the shikimate
biosynthesis pathway, are effective oral vaccines (14).
Salmonella aro mutants are auxotrophic for certain aromatic
compounds such as the three aromatic amino acids tryptophan, tyrosine,
and phenylalanine, as well as para-aminobenzoic acid and
2,3-dihydroxybenzoate. Some of these compounds are not available at
sufficient levels in mammalian tissues to sustain growth of
Salmonella aro mutants, leading to attenuation.
Several S. typhi-based candidate typhoid vaccine
strains harboring aro mutations have been evaluated in
volunteers (16, 35). Two of these, CVD906 and CVD908, are
derivatives of S. typhi strains ISP1820 and Ty2,
respectively, which harbor deletion mutations in aroC and
aroD (17, 34). Although CVD906 and CVD908 are highly immunogenic in volunteers, viable S. typhi
bacteria are detected in the circulation when high doses of vaccine
(108 CFU) are given orally. Since Salmonella
bacteria are disseminated in the blood inside macrophages, mutations
that interfere with macrophage survival may impair this spread.
htrA is a stress response gene in Salmonella that
encodes a periplasmic protease that degrades aberrant proteins
(19). S. typhimurium htrA strains are
attenuated (6) and have an increased sensitivity to hydrogen
peroxide. These data have implicated a role for htrA in the
survival of S. typhimurium in murine macrophages (1). The CVD908 htrA mutant strain has also
recently been evaluated in volunteers (33, 35).
Interestingly, the CVD908 htrA mutant strain was highly
immunogenic, but, unlike with strain CVD908, bacteria were not detected
in the peripheral blood of volunteers. Little is known about how
htrA influences S. typhi virulence in vivo,
although increased susceptibility to macrophage-mediated killing may be involved.
Pathogenicity, attenuation, and immunogenicity of S. typhi-based vaccines are not easy to monitor outside the human
host. It would be useful to have available simple in vivo and in vitro assays that correlate with the behavior of vaccine candidate strains in
humans. To address this issue, and to correlate the lack of systemic
spread in volunteers with a model infection system, we introduced an
htrA mutation into S. typhi BRD691, which
harbors deletions in aroA and aroC. We
subsequently examined the influence of this mutation using in vitro
cell invasion and intracellular survival assays as well as infections
in an in vivo model of human small intestine in SCID mice (10, 17,
31).
 |
MATERIALS AND METHODS |
Bacterial strains, plasmids, and growth conditions.
The
bacterial strains and plasmids used in the course of this study are
described in Table 1. Bacteria were
routinely cultured on L agar or in L broth supplemented with aromatic
compounds as previously described (5). Ampicillin was used
at a final concentration of 50 µg/ml. All chemicals and antibiotics
were obtained from Sigma (Poole, United Kingdom), unless otherwise
stated.
DNA manipulation techniques.
Unless otherwise stated, DNA
manipulations were carried out as described by Sambrook et al.
(30). Restriction enzymes, plasmid vectors, and buffers were
purchased from Boehringer Mannheim or New England Biolabs (Hitchin,
United Kingdom). T4 DNA ligase was purchased from Gibco-BRL (Paisley,
United Kingdom). Chromosomal DNA of S. typhi was
isolated by the method of Hull et al. (18), except that the
crude DNA extract was incubated overnight at 50°C in the presence of
proteinase K and sodium lauryl sarcosinate. Plasmid DNA was purified by
using the WizardPrep system (Promega, Southampton, United Kingdom). DNA
fragments were purified from agarose gels by the method of Tautz and
Renz (36). Electroporation of S. typhi was
carried out as described before (5).
Cloning of the S. typhi htrA gene.
The
cloning and sequencing of the S. typhimurium htrA gene
has been described previously (19). To isolate the
S. typhi htrA gene, BRD691 DNA was purified, cleaved
with HindIII and probed with a DNA fragment encoding the
S. typhimurium htrA gene. This demonstrated that the
S. typhi htrA gene was located on a 3.2-kb fragment
sized similarly to the S. typhimurium htrA gene (data not shown). The S. typhi htrA gene was cloned by
cleaving with HindIII, ligating the 3.2-kb fragment into
the HindIII site of pUC18, and transforming into
Escherichia coli HB101. Five hundred ampicillin-resistant
colonies were isolated and screened for the presence of the
S. typhi htrA gene by using the S. typhimurium htrA gene as the probe. Sixteen positive colonies were
isolated, all of which contained the 3.2-kb HindIII
fragment of S. typhi DNA (data not shown). One of these
plasmids, designated pTYHI, was used for further studies.
Introduction of a defined deletion into the htrA gene
of S. typhi.
Restriction analysis and DNA sequencing of
the S. typhi htrA gene revealed the presence of an
EcoRV and PstI site within the coding sequence
which could be used to generate a deletion (Fig. 1). pTYHI was first cleaved with
EcoRV and then was religated and transformed into E. coli HB101. The resulting plasmid, p
TYAH4, was digested with
EcoRV and SmaI. The 3.57-kb fragment was
recovered and ligated with the 1.6-kb PstI fragment purified
from pTYHI, introducing a 659-bp deletion (pTYHTR). The suicide
replicon pGP704 was used to introduce the htrA deletion into
the chromosome of S. typhi (24). Plasmid
pTYHTR was digested with HindIII and XmnI,
and the resulting 2.53-kb fragment of S. typhi DNA was
ligated into pGP704 and used to transform E. coli
SM10
pir. A plasmid of the expected size was identified by
restriction mapping (data not shown) and designated pTYHTG1.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 1.
Cloning strategy for the construction of a defined
deletion in the S. typhi htrA gene. The final 2.53-kb
fragment is cut with HindIII and cloned into pGP704 to
produce pTYHTG1. Abbreviations: H, HindIII; E,
EcoRV; P, PstI; S, SmaI.
|
|
The construction and characterization of the
S. typhi
Ty2
aroA aroC strain BRD691 has been described previously
(
5). The
plasmid pTYHTG1 was electroporated into BRD691,
followed by screening
for ampicillin-resistant colonies (i.e., those in
which the suicide
replicon had potentially become integrated into the
chromosome
at the
htrA gene). Several of the
ampicillin-resistant colonies
were picked and grown overnight at 37°C
in L broth supplemented
with aromatic compounds but without ampicillin.
The cultures were
diluted to yield ~200 colonies per plate and were
spread onto
L agar. Several hundred colonies were replica plated to
isolate
ampicillin-sensitive colonies (i.e., those in which a double
recombination
event had taken place, resulting in the loss of the
suicide replicon).
A total of 112 such colonies were screened by PCR
with oligonucleotides
corresponding to the regions upstream and
downstream of the deletion
in the
htrA gene. One colony,
designated BRD1116, produced a DNA
fragment of the appropriate size.
The genotype of this strain
was confirmed by Southern hybridization and
by PCR analysis for
the
aroA,
aroC, and
htrA genes (Fig.
2).

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 2.
Southern hybridization and PCR analysis demonstrating
the presence of deletions in the htrA, aroA, and
aroC genes. (A) HindIII-cleaved chromosomal
DNA from BRD1116 (lane 1) and BRD691 (lane 2) reacted with the enhanced
chemiluminescence-labelled probe. (B) Screening of S. typhi colonies for deletions in aroA, aroC,
and htrA by amplifying the deletion region of
chromosomal DNA directly from whole cells by PCR. Lanes: 1, BRD1116
carrying 330-bp htrA deletion fragment; 2, BRD691 carrying
functional 989-bp htrA fragment; 3, BRD1116 carrying 175-bp
deletion aroC fragment; 4, BRD681 carrying 272-bp
aroC fragment; 5, BRD1116 carrying 120-bp aroA
deletion fragment; 6, CVD908 carrying functional 504-bp
aroA fragment; 7, molecular weight standard.
|
|
DNA amplification by PCR.
PCR with S. typhi
colonies was carried out with Taq DNA polymerase and the
GeneAmp kit (Perkin-Elmer Cetus, Norwalk, Conn.) as described
previously (5). The oligonucleotides used in the PCR were
derived from the 5' end and a sequence complementary to the 3' end of
the htrA gene. The oligonucleotides BO5710 (5' GAAATTCATGGCGCTGGGCTCCGGCGTAAT 3') and BO5711 (5'
TGAGGCCAATTTGCGCGGCGGGTGAGTTC 3') mapped at bp 721 to 750 and bp
1710 to 1739 of the S. typhi sequence, respectively.
The two sets of primers used to amplify regions within the
aroA and aroC genes have been described
previously (5).
Southern hybridization.
Chromosomal DNA from S. typhi strains was cleaved with HindIII, followed by
electrophoretic separation on a 1% agarose slab gel and was finally
transferred onto nitrocellulose filters. The filters were hybridized
with the PCR-generated DNA fragments encoding the intact
htrA gene, which had been labelled using the ECL Random Prime kit (Amersham, Little Chalfont, United Kingdom).
Heat stress response.
Bacteria were grown at 30°C
overnight with shaking and were subsequently diluted 1:500, grown to an
optical density at 650 nm of 0.1, and transferred to 45°C. An aliquot
of 100 µl of the culture was removed, serially diluted in sterile
phosphate-buffered saline (PBS), and plated onto L agar in order to
calculate viability after 30, 60, 90, 120, and 150 min.
Oxidative stress response.
Bacteria were grown at 30°C
overnight with shaking and were subsequently diluted 1:500 into L broth
containing 10 mM hydrogen peroxide. Viable counts were taken at 30, 60, 90, 120, and 150 min following the initial subculture.
Cell culture medium.
Dulbecco's modified essential medium
(DMEM) containing L-glutamine and nonessential amino acids
supplemented with 10% heat-inactivated fetal calf serum was used to
maintain the human adenocarcinoma cell lines Caco-2 and HT-29 and the
murine macrophage cell line RAW264.7. RPMI-1640 medium supplemented
with 10% fetal calf serum was used to maintain the human monocytic
cell line U937.
Invasion and intracellular survival assays.
The invasion and
intracellular survival assays were carried out essentially as described
by Lee and Falkow (23). Caco-2 and HT-29 cells were
dispensed into 24-well tissue culture trays (model 25820; Corning) at
5 × 104 cells per well and were incubated until
confluency at 37°C in 5% CO2. RAW264.7 macrophage cells
were seeded at 105 cells per well 24 h before
infection. Bacterial strains were aerobically grown overnight at 37°C
in aro broth. An aliquot of this overnight culture was
diluted 1:1,000 in aro broth and aerobically grown at 37°C
until late exponential phase (optical density at 650 nm, 0.6 to 0.8).
Cells were inoculated with 107 CFU of the bacterial strains
suspended in DMEM (Caco-2 and HT-29) or RPMI-1640 (RAW264.7)
(multiplicity of infection, 50:1) and incubated for 2, 24, 48, and
72 h. Cells were subsequently washed three times with PBS, and
growth of extracellular bacteria was inhibited by replacing the media
with DMEM or RPMI-1640 containing 50 µg of gentamicin per ml.
Cells were further incubated for 1 h, washed three times with PBS,
and lysed by the addition of 1 ml of 0.1% Triton X-100 in PBS for 30 min at 37°C. Lysates were diluted in PBS and plated onto L agar
overnight at 37°C for enumeration of viable bacteria. For infection
periods longer than 2 h, the medium was replaced after 2 h
with DMEM containing 10 µg of gentamicin per ml, until lysis.
Infection of U937 cells was carried out in a similar manner, with the
following modifications. The cells were seeded in 25-cm
2
flasks (model 430639; Costar) at a concentration of 10
5
cells/ml and were incubated with phorbol myristate acetate (10
ng/ml)
for 48 h. The medium was replaced, and viable cells were
enumerated using trypan blue staining. Bacterial strains were
resuspended in RPMI-1640 and added to the cells at a multiplicity
of
infection of 50:1. After a 2-h infection, cells were pelleted
and
washed three times with PBS and the medium was replaced with
RPMI-1640
containing gentamicin (50 µg/ml). After a further 1-h
incubation,
numbers of viable cells were calculated and the medium
was removed. The
cells were washed three times with PBS and lysed
with PBS-Triton X-100
as described above. Intracellular survival
of
Salmonella and
the effect on growth of U937 were determined
over 72-h.
Cell viability assay.
In order to determine the effects of
infection with the vaccine strains on the viability of epithelial
cells, the monotetrazolium (MTT) assay was used (2).
Cells were seeded in 96-well tissue culture plates at a concentration
of 5 × 10
4 cells per well, in 100 µl of medium.
Cells were infected for
1 h at a bacterium/cell ratio of 50:1. The
cells were washed three
times with sterile PBS, and the medium was
replaced with fresh
DMEM without phenol red, containing 50 µg of
gentamicin per ml.
Cells were incubated for 48 h at 37°C. MTT
stock solution (10
µl; 5 mg/ml in DMEM without phenol red) was added
to the cells
and incubated at 37°C for 3 h. Insoluble formazan
salt was dissolved
by the addition of 100 µl of 20% (wt/vol) sodium
dodecyl sulfate
in 10 mM HCl overnight at 37°C. Absorbance of the
converted dye
was measured at a wavelength of 570
nm.
Quantification of IL-8 production by infected epithelial
monolayers.
HT-29 cells were seeded in six-well tissue culture
plates at a concentration of 1 × 105 to 2 × 105 cells/ml, grown until confluency, and infected as
detailed above. At 3, 6, 24, 48, and 72 h after the infection, the
supernatant was removed, frozen in liquid nitrogen, and stored at
70°C. Interleukin-8 (IL-8) enzyme-linked immunosorbent assays of
the supernatants were subsequently performed as previously described
(9), with optimal concentrations of polyclonal goat
anti-human IL-8 antibodies (R & D Systems, Minneapolis, Minn.) as
capturing antibodies and polyclonal rabbit anti-human IL-8 antibodies
(Endogen, Boston, Mass.) as detecting antibodies. Alkaline
phosphatase-labelled monoclonal mouse anti-rabbit immunoglobulin G
(Sigma) was used as a second-step antibody. Bound alkaline phosphatase
was visualized with the substrate p-nitrophenylphosphate
(Sigma). The sensitivity of the IL-8 enzyme-linked immunosorbent
assay was 50 pg/ml.
Human intestinal xenograft infections.
We recently described
a xenogeneic model of human small intestine as a system to study
Salmonella infection of nontransformed epithelial cells in
vivo (10, 18, 31). Briefly, pieces of human fetal intestine
(mean gestational age = 12 weeks) were implanted subcutaneously in
CB-17 SCID mice and were allowed to develop for 12 to 16 weeks. During
this time the xenografts develop a mucosa which shows morphological and
functional similarities to that of pediatric intestine (31).
All procedures were performed with the full approval of the Cambridge
Local Ethics Committee and in accordance with Home Office guidelines.
Bacteria were grown to late exponential phase and were resuspended in
sterile PBS to a concentration of 5 × 10
8 CFU/ml.
SCID mice were subcutaneously inoculated with 0.1 ml
of the bacterial
strains, using a Microlance 3 needle (25 gauge;
Becton Dickinson,
Drogheda, Ireland) inserted through the xenograft
wall into the lumen.
At 6 and 24 h following infection, mice were
killed and the
xenografts, spleens, and livers were removed. The
organs were
homogenized in sterile PBS containing 0.1% Triton
X-100, serially
diluted, and plated onto L agar in order to enumerate
bacteria. Spleen
and liver counts were pooled to determine translocation.
Half of each
xenograft was organ cultured in DMEM containing 50
µg of gentamicin
per ml for 1 h at 37°C prior to homogenization.
Mice without
intestinal xenografts that had been inoculated intraperitonally
with
either 10
6, 10
7, or 10
8 bacteria
were killed at 6, 24, 48, and 72 h, and pooled spleen
and liver
bacterial counts were
made.
Statistical analysis.
Data are expressed as means ± standard errors of the means (SEM). Statistical significance of
differences between groups was assessed by Mann-Whitney U tests on
untransformed data.
 |
RESULTS |
Heat and oxidative stress response of BRD691 and
BRD1116.
The E. coli HtrA periplasmic protease
has been shown to be essential for bacterial growth at elevated
temperatures, as it is required to degrade thermally aggregated
proteins (22). However, in S. typhimurium
the htrA gene is essential for survival in medium containing
significant levels of hydrogen peroxide but not for survival at
elevated temperatures (19). The ability of BRD1116 to
survive increased temperatures and exposure to hydrogen peroxide was
therefore examined. BRD1116 exhibited properties similar to those of
S. typhimurium htrA for both heat and oxidative shock (Fig. 3) in that there was no significant
difference in the ability to withstand increased temperatures
but a markedly increased susceptibility to oxidative stress compared
with that of BRD691 was observed.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 3.
The effect of 10 mM H2O2 (A) and
a growth temperature of 42°C (B) on the viability of the
S. typhi htrA mutant BRD1116 and the parent strain
BRD691. Data are means ± SEM (error bars) (n = 6).
|
|
Decreased epithelial intracellular survival of BRD1116 compared
with BRD691.
The ability of BRD1116 and BRD691 to invade and
survive in the human adenocarcinoma cell lines Caco-2 and HT-29 was
examined. These cell lines, which form monolayers and differentiate to
different extents when confluent, forming a well-developed brush border membrane in the case of Caco-2, have been used extensively as models
for human intestinal epithelium (29). There was no
significant difference between BRD691 or BRD1116 invasion of Caco-2 or
HT-29 monolayers (Fig. 4), indicating
that htrA is not directly involved in the invasion process.
After 48 h there was a 10-fold decrease in the numbers of viable
BRD1116 recovered in comparison to BRD691. By 72 h ~100-fold
less viable BRD1116 was recovered. These results suggest that the
S. typhi HtrA protease is required for prolonged survival within intestinal epithelial cells.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 4.
Invasion and intracellular survival of BRD691 and
BRD1116 in the human intestinal epithelial cell lines Caco-2 (A) and
HT-29 (B) over 72 h. Data are means ± SEM (error bars)
(n = 6).
|
|
The effect of infection with the two
S. typhi strains
on the viability of Caco-2 and HT-29 intestinal epithelial cells was
also examined, with MTT used as a marker of cell viability. There
was
no significant effect on cell viability following infection
with either
strain in either cell line after 48 h (Table
2),
suggesting that these strains do not
cause significant differences
in epithelial cell death upon invasion.
Intracellular survival of BRD1116 and BRD691 within the human
monocytic cell line U937 and the macrophage cell line RAW264.7.
The ability of BRD1116 and BRD691 to invade and survive within
activated U937 cells (a human monocytic cell line) and the murine
macrophage cell line RAW264.7 was then examined. Activated U937 cells
have been used extensively as a human macrophage model (28).
There was no significant difference between the two strains in their
ability to invade and survive within this cell line (Fig. 5A), as both strains were eliminated from
the culture within 72 h. There was no significant difference in
growth or viability of U937 cells infected with either strain,
compared to uninfected controls (data not shown).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 5.
Invasion and intracellular survival of BRD691 and
BRD1116 in the human monocytic cell line U937 (A) and the murine
macrophage cell line RAW264.7 (B) over 72 h. Data are means ± SEM (error bars) (n = 6).
|
|
There was a three- to fourfold decrease in the numbers of viable
BRD1116 recovered from RAW264.7 cells at 4 and 24 h after
infection, suggesting a decreased ability of BRD1116 to survive
within
this cell line. After 48 h however, there was no difference
in the
numbers of viable bacteria recovered for either
strain.
BRD1116 is attenuated in an in vivo model system of human
intestine.
A xenogeneic model of human intestine was used to
examine S. typhi invasion, intracellular survival and
translocation to secondary sites of infection. Using the gentamicin
resistance assay to quantify intracellular bacteria, it was possible to
compare the ability of the two vaccine strains to invade the intestinal
mucosa. In additional experiments E. coli DH5
was
inoculated in vivo into the xenograft lumen to test the ability of the
system to exclude a noninvasive, nonpathogenic organism. At 6 h
following infection there was no significant difference between BRD1116
and BRD691 either in the levels of total bacteria present within the
tissue or in the levels of intracellular bacteria (Fig.
6A). Very few viable E. coli
were recovered, indicating that the xenograft mucosa forms a tight
monolayer, impermeable to noninvasive organisms. Tissue examined
24 h after infection (Fig. 6B) showed a clear decrease in the
numbers of viable intracellular BRD1116 compared to BRD691.
Translocation of BRD1116 to secondary sites of infection, e.g., spleen
and liver, was significantly reduced compared to that of BRD691 after
6 h and was completely abrogated within 24 h (Fig. 6C).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 6.
Invasion and intracellular survival of BRD691 and
BRD1116 in an in vivo xenograft model of human intestine after 6 h
(A) and 24 h (B) of infection. Shaded bars represent total counts
in the xenografts, and open bars represent counts obtained from
xenografts incubated with gentamicin prior to homogenization. (C)
Translocation of bacteria to secondary sites of infection (spleen plus
liver counts) over 6 h (shaded bars) and 24 h (open bar).
Data are means ± SEM (error bars) (n = 4).
|
|
BRD691 and BRD1116 were assessed for the ability to invade and persist
within SCID mice that did not carry intestinal xenografts.
Mice of the
same age as those used for xenograft experiments were
infected
intraperitonally. Spleen and liver counts (Fig.
7) showed
no significant difference in
levels of the two bacterial strains
over a 72-h period, indicating that
the
htrA gene is not required
for survival within the
reticuloendothelial system in this model.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 7.
Persistence of BRD691 and BRD1116 in spleens and livers
of SCID mice infected intraperitonally with 107 bacteria
over 72 h. Data are means ± SEM (error bars) (n = 4).
|
|
Ability of S. typhi vaccine strains to elicit an
increase in the proinflammatory chemokine IL-8 in infected epithelial
cells.
Invasive bacterial strains provoke a cascade of
proinflammatory host events following invasion of epithelial cells
(9, 21, 25). An important proinflammatory signal molecule
during this event is the chemokine IL-8, which is a chemoattractant for neutrophils. The ability of BRD1116 and BRD691 to upregulate the production of IL-8 following infection of HT-29 intestinal epithelial monolayers was compared over a 72-h period (Fig.
8). BRD1116 elicited a slightly smaller
IL-8 response than the parent strain at all time points. However, these
differences were not found to be significant (P > 0.05).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 8.
Secretion of IL-8 by HT-29 cells following infection
with BRD691 or BRD1116. Data are means ± SEM (error bars)
(n = 2).
|
|
 |
DISCUSSION |
We have examined the properties of two candidate S. typhi live oral typhoid vaccine strains using in vitro and in vivo
assays. These assays assessed the response of the strains to heat and oxidative stress, their ability to invade and survive within tissue culture cells, their ability to induce epithelial proinflammatory cytokine production in vitro, and their ability to invade epithelial cells and to disseminate in a human intestinal xenograft model. In
common with S. typhimurium htrA mutants, BRD1116 has an
increased susceptibility to oxidative stress in comparison to BRD691,
the S. typhi aroA aroC parent strain. The ability of
BRD1116 to survive in the human macrophage cell line U937 or the
murine macrophage cell line over 72 h was not reduced, although
there was a reduction in viable BRD1116 bacteria recovered from
RAW264.7 cells within the first 24 h of infection, compared to
BRD691. BRD1116 was defective in its ability to survive in the human
intestinal epithelial cell lines Caco-2 and HT-29 over a 72-h period.
These data suggest that the HtrA periplasmic protease is required for
survival during the initial invasion of the intestinal mucosa but not
the subsequent invasion of recruited macrophages. We recognize,
however, that the U937 macrophage cell line manifests impaired nitrite
production (28) and in this respect may not be an accurate
model of macrophage killing in vivo. The intracellular survival of the
two strains may therefore be more accurately observed within the murine
macrophage cell line RAW264.7, although killing of S. typhi strains within this cell line is likely to be mainly due to
host-restricted mechanisms. A previous report has demonstrated, though,
that S. typhimurium htrA mutants have been shown to
have an increased susceptibility to killing in isolated murine
peritoneal macrophages (1).
Infections of Caco-2 and HT-29 cell lines demonstrated that over
72 h, these cells were capable of inhibiting the growth of internalized S. typhi vaccine strains. Internalized
Salmonella bacteria have been widely shown to replicate
within the epithelium (24). A recent ultrastructural report
showed a simultaneous degradation and replication of intracellular
bacteria within Caco-2 cells (37). Mutants of
Salmonella that contain deletions in the aro
genes are impaired in their ability to replicate, which shifts
this equilibrium so that there is a reduction in the number of
intracellular bacteria over time. Although the bactericidal mechanisms of epithelial cells are largely unknown, the data
shown here suggest that htrA is required by the bacteria to
respond to this host response.
In order to compare the survival and replication properties of BRD691
and BRD1116 in nontransformed human intestinal epithelium, a model
using human intestine implanted in SCID mice was utilized. The decrease
in intracellular survival and translocation exhibited by BRD1116
following intralumenal infection in this system provides additional
evidence for epithelium-mediated killing of bacteria in vivo. This is
particularly apparent compared to intraperitonal infection, in which no
significant difference in the ability of the htrA mutant and
the parent strain to infect systemic organs like the spleen and liver
was noted. Whereas the intestinal xenografts contain a completely human
epithelium and neighboring human intraepithelial lymphocytes, the
lamina propria contains ~70% human cells and 30% murine cells in a
chimeric mixture. Moreover, S. typhi is host restricted
to humans and does not cause a typhoid-like disease in SCID mice. Thus,
although the initial interactions of the invasive bacteria and the
xenograft epithelium are reflective of the in vivo cross-talk that may
take place following administration of the vaccine strain to humans,
the subsequent invasion of murine leukocytes and systemic translocation
to other organs may be less instructive. The inability of BRD1116 to
spread to the spleen and liver in infected animals may also, for
example, be due to preferential killing by CD68+ human
macrophages present in the xenograft mucosa (unpublished findings) or
may be due to increased host-restricted killing by murine
macrophages and neutrophils. The results obtained from this SCID model
do, however, provide in vivo evidence for the intestinal mucosa as a
site of attenuation of BRD1116.
A recent study on closely related S. typhi htrA live
vaccine strains administered to volunteers reported mild diarrhea in a
small number of subjects (34). A possible mechanism
postulated for these findings was a change in the interaction of the
bacteria with the mucosa, resulting in a different cytokine release
pattern. One of the important cytokines whose production is
increased following invasion by pathogenic bacteria is the
neutrophil chemoattractant IL-8 (9, 21, 25). In this study,
no significant difference was observed in the ability of BRD1116
and BRD691 to induce epithelial IL-8, which demonstrates that the
htrA deletion does not significantly alter the
proinflammatory potential of this strain.
BRD1116 and other S. typhi htrA mutant strains are
currently undergoing phase 1 clinical trials and may ultimately form
the basis of multivalent vaccines expressing heterologous antigens from
a number of pathogenic microorganisms. Thus, the ability to ascertain
the in vivo role of mutations in htrA and similar genes will
be increasingly important. The assays described herein, particularly
the intestinal xenograft assay, should prove of particular value in
this regard.
 |
ACKNOWLEDGMENTS |
This work was primarily supported by the Medeva Vaccine Research
Unit. G.D. was supported by a grant from the Wellcome Trust. D.C.L. is
a collaborative student funded by the Medical Research Council. L.E. is
a recipient of a Career Development Award of the Crohn's and Colitis
Foundation of America.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Medeva Vaccine
Research Unit, Department of Biochemistry, Imperial College of Science, Technology and Medicine, Exhibition Road, London SW7 2AY, United Kingdom. Phone: 0171 594 5211. Fax: 0171 584 9467. E-mail:
Steve_Chatfield{at}medeva.ccmail.compuserve.com.
Editor:
P. J. Sansonetti
 |
REFERENCES |
| 1.
|
Baumler, A. J.,
J. G. Kusters,
I. Stojiljkovic, and F. Heffron.
1994.
Salmonella typhimurium loci involved in survival within macrophages.
Infect. Immun.
62:1623-1630[Abstract/Free Full Text].
|
| 2.
|
Carmichael, J.,
W. G. Dgraff,
A. F. Gazdar,
J. D. Minna, and J. B. Mitchell.
1987.
Evaluation of a tetrazolium-based semiautomated colorimetric assay assessment of chemosensitivity testing.
Cancer Res.
47:936-942[Abstract/Free Full Text].
|
| 3.
|
Carter, P. B., and F. M. Collins.
1974.
The route of enteric infection in normal mice.
J. Exp. Med.
139:1189-1203[Abstract].
|
| 4.
|
Chatfield, S. N.,
I. G. Charles,
A. J. Makoff,
M. D. Oxer,
G. Dougan,
D. Pickard,
D. Slater, and N. F. Fairweather.
1992.
Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine.
Bio/Technology
10:888-892[Medline].
|
| 5.
|
Chatfield, S. N.,
N. F. Fairweather,
I. G. Charles,
D. Pickard,
M. M. Levine,
D. Hone,
M. Posada,
R. A. Strugnell, and G. Dougan.
1992.
Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine.
Vaccine
10:53-60[Medline].
|
| 6.
|
Chatfield, S. N.,
K. Strahan,
D. Pickard,
I. G. Charles,
C. E. Hormaeche, and G. Dougan.
1992.
Evaluation of Salmonella typhimurium strains harboring defined mutations in htrA and aroA in the murine salmonellosis model.
Microb. Pathog.
12:145-151[Medline].
|
| 7.
|
Chen, L. M.,
K. Kaniga, and J. E. Galán.
1996.
Salmonella spp. are cytotoxic for cultured macrophages.
Mol. Microbiol.
21:1101-1115[Medline].
|
| 8.
|
Clark, M. A.,
M. A. Jepson,
N. L. Simmons, and B. H. Hirst.
1994.
Preferential interaction of Salmonella typhimurium with mouse Peyer's patch M cells.
Res. Microbiol.
145:543-552[Medline].
|
| 9.
|
Eckmann, L.,
M. F. Kagnoff, and J. Fierer.
1993.
Epithelial cells secrete the chemokine interleukin-8 in response to bacterial entry.
Infect. Immun.
61:4569-4574[Abstract/Free Full Text].
|
| 10.
|
Eckmann, L.,
W. F. Stenson,
T. C. Savidge,
D. C. Lowe,
K. E. Barrett,
J. Fierer,
J. R. Smith, and M. F. Kagnoff.
1997.
Role of intestinal epithelial cells in the host secretory response to invasive bacteria.
J. Clin. Investig.
100:296-309[Medline].
|
| 11.
|
Fouts, T. R.,
G. K. Lewis, and D. M. Hone.
1995.
Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine.
Vaccine
13:561-569[Medline].
|
| 12.
|
Gonzalez, C.,
D. Hone,
F. R. Noriega,
C. O. Tacket,
J. R. Davis,
G. Losonsky,
J. P. Nataro,
S. Hoffman,
A. Malik,
E. Nardin,
M. B. Sztein,
D. G. Heppner,
T. R. Fouts,
A. Isibasi, and M. M. Levine.
1994.
Salmonella typhi vaccine strain CVD908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.
J. Infect. Dis.
169:927-931[Medline].
|
| 13.
|
Hohmann, E. L.,
C. A. Oletta,
K. P. Killeen, and S. I. Miller.
1996.
PhoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers.
J. Infect. Dis.
173:1408-1414[Medline].
|
| 14.
|
Hoiseth, S. K., and B. A. D. Stocker.
1981.
Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines.
Nature (London)
291:238-239[Medline].
|
| 15.
|
Hone, D. M.,
A. M. Harris,
S. Chatfield,
G. Dougan, and M. M. Levine.
1991.
Construction of genetically defined double aro mutants of Salmonella typhi.
Vaccine
9:810-816[Medline].
|
| 16.
|
Hone, D. M.,
C. O. Tacket,
A. M. Harris,
B. Kay,
G. Losonsky, and M. M. Levine.
1992.
Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine.
J. Clin. Investig.
90:412-420.
|
| 17.
|
Huang, G. T.-J.,
L. Eckmann,
T. C. Savidge, and M. F. Kagnoff.
1996.
Infection of human intestinal epithelial cells with invasive bacteria upregulates apical intercellular adhesion molecule-1 (ICAM-1) expression and neutrophil adhesion.
J. Clin. Investig.
98:572-583[Medline].
|
| 18.
|
Hull, R. A.,
R. E. Gill,
P. Hsu,
B. H. Minshew, and S. Falkow.
1981.
Construction and expression of recombinant plasmids encoding type 1 and mannose resistant pili from a urinary tract infection Escherichia coli isolate.
Infect. Immun.
33:933-938[Abstract/Free Full Text].
|
| 19.
|
Johnson, K.,
I. G. Charles,
G. Dougan,
D. Pickard,
P. O'Gaora,
G. Costa,
T. Ali,
I. Miller, and C. Hormaeche.
1991.
The role of a stress-response protein in Salmonella typhimurium virulence.
Mol. Microbiol.
5:401-407[Medline].
|
| 20.
|
Jones, B. D.,
N. Ghori, and S. Falkow.
1994.
Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches.
J. Exp. Med.
180:15-23[Abstract/Free Full Text].
|
| 21.
|
Jung, H. C.,
L. Eckmann,
S.-K. Yang,
A. J. Panja,
J. Fierer,
E. Morzycka-Wroblewska, and M. F. Kagnoff.
1995.
A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion.
J. Clin. Investig.
95:55-65.
|
| 22.
|
Laskowska, E.,
D. Kuczyflska-Wicnik,
J. Skrko-Glonek, and A. Taylor.
1996.
Degradation by proteases Lon, Clp and HtrA, of Escherichia coli proteins aggregated in vivo by heat shock; HtrA protease action in vivo and in vitro.
Mol. Microbiol.
22:555-571[Medline].
|
| 23.
|
Lee, C. A., and S. Falkow.
1990.
The ability of Salmonella to enter mammalian cells is affected by bacterial growth state.
Proc. Natl. Acad. Sci. USA
87:4304-4308[Abstract/Free Full Text].
|
| 24.
|
Leung, K. Y., and B. B. Finlay.
1991.
Intracellular replication is essential for the virulence of Salmonella typhimurium.
Proc. Natl. Acad. Sci. USA
88:11470-11474[Abstract/Free Full Text].
|
| 25.
|
McCormick, B. A.,
S. P. Colgan,
C. Delp-Archer,
S. I. Miller, and J. L. Madara.
1993.
Salmonella typhimurium attachment to human intestinal epithelial monolayers: transcellular signalling to subepithelial neutrophils.
J. Cell Biol.
123:895-907[Abstract/Free Full Text].
|
| 26.
|
Miller, V. L., and J. J. Mekalanos.
1988.
A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR.
J. Bacteriol.
170:2575-2583[Abstract/Free Full Text].
|
| 27.
|
Monack, D. M.,
B. Raupach,
A. E. Hromockyi, and S. Falkow.
1996.
Salmonella typhimurium invasion induces apoptosis in infected macrophages.
Proc. Natl. Acad. Sci. USA
95:9833-9838.
|
| 28.
|
Ralph, P.
1986.
Macrophage cell lines, p. 45.1-45.15.
In
D. M. Weir (ed.), Handbook of experimental immunology, 4th ed., vol. 2. Cellular immunology. Blackwell Scientific Publications, Oxford, United Kingdom.
|
| 29.
|
Rousset, M.
1986.
The human colon carcinoma cell lines HT-29 and Caco-2. Two in vitro models for the study of intestinal differentiation.
Biochimie
68:1035-1040[Medline].
|
| 30.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
|
| 31.
|
Savidge, T. C.,
A. L. Morey,
D. J. P. Ferguson,
K. A. Fleming,
A. N. Shmakov, and A. D. Phillips.
1995.
Human intestinal development in a severe-combined immunodeficient xenograft model.
Differentiation
58:361-371[Medline].
|
| 32.
|
Strugnell, R.,
G. Dougan,
S. N. Chatfield,
I. G. Charles,
N. F. Fairweather,
J. Tite,
J. L. Li,
J. Beesley, and M. Roberts.
1992.
Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis.
Infect. Immun.
60:3994-4002[Abstract/Free Full Text].
|
| 33.
|
Tacket, C. O.,
D. M. Hone,
R. Curtiss III,
S. M. Kelly,
G. Losonsky,
L. Guers,
A. M. Harris,
R. Edelman, and M. M. Levine.
1992.
Comparison of the safety and immunogenicity of Salmonella typhi strains in adult volunteers.
Infect. Immun.
60:536-541[Abstract/Free Full Text].
|
| 34.
|
Tacket, C. O.,
D. M. Hone,
G. A. Losonsky,
L. Guers,
R. Edelman, and M. M. Levine.
1992.
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
Vaccine
10:443-446[Medline].
|
| 35.
|
Tacket, C. O.,
M. B. Sztein,
G. A. Losonsky,
S. S. Wasserman,
J. P. Nataro,
R. Edelman,
D. Pickard,
G. Dougan,
S. N. Chatfield, and M. M. Levine.
1997.
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans.
Infect. Immun.
65:452-456[Abstract].
|
| 36.
|
Tautz, D., and M. Renz.
1992.
An optimised freeze-squeeze method for the recovery of DNA fragments from agarose gels.
Anal. Biochem.
132:14-19.
|
| 37.
|
Wells, C. L.,
E. M. A. van de Westerlo,
R. P. Jechorek, and S. L. Erlandsen.
1996.
Intracellular survival of enteric bacteria in cultured human enterocytes.
Shock
6:27-34[Medline].
|
| 38.
|
Yang, S.,
L. Eckmann,
A. Panja, and M. F. Kagnoff.
1997.
Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells.
Gastroenterology
113:1214-1223[Medline].
|
Infection and Immunity, February 1999, p. 700-707, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bishop, A., House, D., Perkins, T., Baker, S., Kingsley, R. A., Dougan, G.
(2008). Interaction of Salmonella enterica serovar Typhi with cultured epithelial cells: roles of surface structures in adhesion and invasion. Microbiology
154: 1914-1926
[Abstract]
[Full Text]
-
Sebkova, A., Karasova, D., Crhanova, M., Budinska, E., Rychlik, I.
(2008). aro Mutations in Salmonella enterica Cause Defects in Cell Wall and Outer Membrane Integrity. J. Bacteriol.
190: 3155-3160
[Abstract]
[Full Text]
-
Bishop, A. L., Baker, S., Jenks, S., Fookes, M., Gaora, P. O, Pickard, D., Anjum, M., Farrar, J., Hien, T. T., Ivens, A., Dougan, G.
(2005). Analysis of the Hypervariable Region of the Salmonella enterica Genome Associated with tRNAleuX. J. Bacteriol.
187: 2469-2482
[Abstract]
[Full Text]
-
Husseiny, M. I., Hensel, M.
(2005). Rapid Method for the Construction of Salmonella enterica Serovar Typhimurium Vaccine Carrier Strains. Infect. Immun.
73: 1598-1605
[Abstract]
[Full Text]
-
Londono-Arcila, P., Freeman, D., Kleanthous, H., O'Dowd, A. M., Lewis, S., Turner, A. K., Rees, E. L., Tibbitts, T. J., Greenwood, J., Monath, T. P., Darsley, M. J.
(2002). Attenuated Salmonella enterica Serovar Typhi Expressing Urease Effectively Immunizes Mice against Helicobacter pylori Challenge as Part of a Heterologous Mucosal Priming-Parenteral Boosting Vaccination Regimen. Infect. Immun.
70: 5096-5106
[Abstract]
[Full Text]
-
Qian, F., Pan, W.
(2002). Construction of a tetR-Integrated Salmonella enterica Serovar Typhi CVD908 Strain That Tightly Controls Expression of the Major Merozoite Surface Protein of Plasmodium falciparum for Applications in Human Vaccine Production. Infect. Immun.
70: 2029-2038
[Abstract]
[Full Text]
-
Foulongne, V., Walravens, K., Bourg, G., Boschiroli, M. L., Godfroid, J., Ramuz, M., O'Callaghan, D.
(2001). Aromatic Compound-Dependent Brucella suis Is Attenuated in Both Cultured Cells and Mouse Models. Infect. Immun.
69: 547-550
[Abstract]
[Full Text]
-
Resto-Ruiz, S. I., Sweger, D., Widen, R. H., Valkov, N., Anderson, B. E.
(2000). Transcriptional Activation of the htrA (High-Temperature Requirement A) Gene from Bartonella henselae. Infect. Immun.
68: 5970-5978
[Abstract]
[Full Text]
-
McSorley, S. J., Jenkins, M. K.
(2000). Antibody Is Required for Protection against Virulent but Not Attenuated Salmonella enterica Serovar Typhimurium. Infect. Immun.
68: 3344-3348
[Abstract]
[Full Text]
-
Tacket, C. O., Sztein, M. B., Wasserman, S. S., Losonsky, G., Kotloff, K. L., Wyant, T. L., Nataro, J. P., Edelman, R., Perry, J., Bedford, P., Brown, D., Chatfield, S., Dougan, G., Levine, M. M.
(2000). Phase 2 Clinical Trial of Attenuated Salmonella enterica Serovar Typhi Oral Live Vector Vaccine CVD 908-htrA in U.S. Volunteers. Infect. Immun.
68: 1196-1201
[Abstract]
[Full Text]
-
Foulongne, V., Bourg, G., Cazevieille, C., Michaux-Charachon, S., O'Callaghan, D.
(2000). Identification of Brucella suis Genes Affecting Intracellular Survival in an In Vitro Human Macrophage Infection Model by Signature-Tagged Transposon Mutagenesis. Infect. Immun.
68: 1297-1303
[Abstract]
[Full Text]